help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shiroozu, A.
Right arrow Articles by Yoshizumi, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shiroozu, A.
Right arrow Articles by Yoshizumi, T.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*METHIMAZOLE
*PERCHLORIC ACID
*POTASSIUM
*POTASSIUM PERCHLORATE

Journal of Clinical Endocrinology & Metabolism, Vol 63, 125-128, Copyright © 1986 by Endocrine Society

ARTICLES

Treatment of hyperthyroidism with a small single daily dose of methimazole

A Shiroozu, K Okamura, H Ikenoue, K Sato, T Nakashima, M Yoshinari, M Fujishima and T Yoshizumi

The duration of action of methimazole (MMI) was studied in patients with hyperthyroidism due to Graves' disease. Perchlorate discharge tests performed 24 h after MMI administration revealed greater than 10% discharge in 77% of 53 patients who received a single dose of 15 mg MMI and in 74% of 23 patients who received 30 mg. The mean percent discharges were 41.5 +/- 26.4% (+/- SD) and 35.4 +/- 28.0, respectively. Based on these results, hyperthyroidism was treated with a single daily dose (SDD) of 15 mg in 43 patients and with 30 mg in 32 patients, and the results were compared with retrospective analysis of 50 patients who were treated with divided doses of MMI (10 mg, 3 times daily). Within 12 weeks, 93% of the patients treated with 15 mg SDD, 91% treated with 30 mg SDD, and 86% treated with divided doses were euthyroid. The mean times to achieve euthyroidism in these patients were 5.3 +/- 3.6 (+/- SD), 5.3 +/- 3.1, and 5.6 +/- 3.0 weeks, respectively. Side-effects occurred in 2 patients treated with 15 mg SDD and in 6 treated with 30 mg SDD. We conclude that a single daily dose of 15 mg MMI is not only effective in most patients with Graves' hyperthyroidism, but also less frequently causes adverse effects.


This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
H. Nakamura, J. Y. Noh, K. Itoh, S. Fukata, A. Miyauchi, N. Hamada, and Working Group of the Japan Thyroid Association for
Comparison of Methimazole and Propylthiouracil in Patients with Hyperthyroidism Caused by Graves' Disease
J. Clin. Endocrinol. Metab., June 1, 2007; 92(6): 2157 - 2162.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
F. J Vilchez, I. Torres, A. Garcia-Valero, C. Lopez-Tinoco, A. de los Santos, and M. Aguilar-Diosdado
Concomitant Agranulocytosis and Hepatotoxicity After Treatment with Carbimazole
Ann. Pharmacother., November 1, 2006; 40(11): 2059 - 2063.
[Abstract] [Full Text] [PDF]

Home page
 CMAJHome page
J. Ginsberg
Diagnosis and management of Graves' disease
Can. Med. Assoc. J., March 4, 2003; 168(5): 575 - 585.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. A. Rivkees, C. Sklar, and M. Freemark
The Management of Graves' Disease in Children, with Special Emphasis on Radioiodine Treatment
J. Clin. Endocrinol. Metab., November 1, 1998; 83(11): 3767 - 3776.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1986 by The Endocrine Society